We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.
- Authors
Gancberg, D; Di Leo, A; Cardoso, F; Rouas, G; Pedrocchi, M; Paesmans, M; Verhest, A; Bernard-Marty, C; Piccart, M J; Larsimont, D
- Abstract
The humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) is a new treatment modality for metastatic breast cancer, the efficacy of which is directly correlated with the HER-2 status of the tumour, evaluated either by immunohistochemistry (IHC) and/or by fluorescence in situ hybridisation (FISH). This analysis is generally performed on the primary tumour. There are few data regarding the HER-2 status in the corresponding distant metastases.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Vol 13, Issue 7, p1036
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdf252